Baird maintained a Neutral rating on Theravance Biopharma (NASDAQ: TBPH), and cut the price target to $14.00 (from $17.00), following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE